Abstract
Hypoxia-inducible factor (HIF) is a dimeric transcription factor identified as the major regulator of hypoxic responses in cells. Its activity is mainly regulated by protein stability. In well-oxygenated tissues prolyl hydroxylases hydroxylate HIF-1α and HIF-2α protein to provoke their proteasomal degradation. Under hypoxia the α-subunits are stabilized and dimerize with ß-subunits to constitute active transcriptional complexes. As the α-subunits are constantly translated and degraded, any interference with cellular translation will alter HIF-α expression and HIF activity. Cytokines such as interleukins or interferons as well as growth factors such as vascular endothelial growth factor or insulin-like growth factor are good examples of hormones that affect transcription, translation, or degradation of HIF-1α. In turn, HIF specific target genes also modulate the expression and/or signaling quality of cytokines or growth factors to create signal amplifying/intercepting cellular networks. We define how these signaling circuits promote or delay the progression of diseases and describe potential outcomes for patients.
Keywords: Hypoxia-inducible factor, cancer, insulin, insulin-like growth factor, interferon, interleukin, mTOR, tumor necrosis factor, vascular endothelial growth factor.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Volume: 11 Issue: 2
Author(s): Nathalie Dehne, Dominik Fuhrmann and Bernhard Brune
Affiliation:
Keywords: Hypoxia-inducible factor, cancer, insulin, insulin-like growth factor, interferon, interleukin, mTOR, tumor necrosis factor, vascular endothelial growth factor.
Abstract: Hypoxia-inducible factor (HIF) is a dimeric transcription factor identified as the major regulator of hypoxic responses in cells. Its activity is mainly regulated by protein stability. In well-oxygenated tissues prolyl hydroxylases hydroxylate HIF-1α and HIF-2α protein to provoke their proteasomal degradation. Under hypoxia the α-subunits are stabilized and dimerize with ß-subunits to constitute active transcriptional complexes. As the α-subunits are constantly translated and degraded, any interference with cellular translation will alter HIF-α expression and HIF activity. Cytokines such as interleukins or interferons as well as growth factors such as vascular endothelial growth factor or insulin-like growth factor are good examples of hormones that affect transcription, translation, or degradation of HIF-1α. In turn, HIF specific target genes also modulate the expression and/or signaling quality of cytokines or growth factors to create signal amplifying/intercepting cellular networks. We define how these signaling circuits promote or delay the progression of diseases and describe potential outcomes for patients.
Export Options
About this article
Cite this article as:
Dehne Nathalie, Fuhrmann Dominik and Brune Bernhard, Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020008
DOI https://dx.doi.org/10.2174/1871525711311020008 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Recent Patents on Inflammation & Allergy Drug Discovery Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas
Current Cancer Drug Targets TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Current Medicinal Chemistry Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers
Current Pharmaceutical Biotechnology Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments
Current Signal Transduction Therapy The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology